

**Virginia Medicaid**  
**Pharmacy & Therapeutics Committee Meeting**  
Agenda  
600 East Broad Street – 7<sup>th</sup> Floor Conference Rooms  
Richmond, VA 23219  
**Thursday, April 19, 2018 – 10 AM**

**Welcome and Comments**

**Jennifer Lee, MD, Agency Director**

**Call to Order**

**Kate Neuhausen, MD, MPH, CMO, Chair**

**Drug Utilization Review (DUR) Board Report**

**Rachel Cain, PharmD**

**Approval of Minutes from October 20, 2017 Meeting**

**P&T Committee Members**

**PDL Management**

**P&T Committee Members**

• **PDL Phase I – New Drug Review (Therapeutic Class)**

**Brand Drugs**

- Cinvanti™ & Varubi® (*Antiemetic/Antivertigo Agents*)
- Duzallo® (*Antihyperuricemics*)
- Symproic® (*GI Motility, Chronic*)
- QVAR® Redihaler™ & Trelegy™ Ellipta® a (*Glucocorticoids, Inhaled*)
- Vyzulta™ (*Ophthalmics, Glaucoma Agents*)
- ZoDex® (*Glucocorticoids, Oral*)

**Generics Drugs or New Dosage Forms**

- Carvedilol ER, first generic for Coreg CR™ (*Beta-Blockers*)
- Paroxetine, first generic for Brisdelle® (*Antidepressants, SSRIS*)
- Timolol, first generic for Istalol® (*Ophthalmics, Glaucoma Agents*)
- Esomeprazole magnesium, first generic, for Nexium® 24 HR (OTC) (*PPI*)

• **PDL Phase II – Annual Review**

**Analgesics**

- Antimigraine Agents
- Non-Steroidal Anti-Inflammatory Drugs (NSAID) (*includes Cox-2 inhibitors and topical agents*)
- Opioid Analgesics & Dependency (**Closed class**) (*includes oral buprenorphine & methadone*)
- Opioids: Short Acting (*includes combination drugs and lozenges*)
- Topical Agents & Anesthetics

**Antibiotics / Anti-Infectives**

- Antibiotics (*topical*)
- Antifungals (*oral*)
- Cephalosporins (*Second and Third Generations*)
- Gastrointestinal
- Ketolides & Macrolides (*Adult and Pediatric*)
- Quinolones (*Second and Third Generations*)
- Quinolones (*Otic*)

**Antivirals**

- Antivirals for Herpes (HSV)
- Antivirals for Influenza

**Blood Modifiers**

- Antihyperuricemics
- Erythropoiesis Stimulating Proteins

**Cardiac**

- Anticoagulants (*includes oral agents, low molecular weight heparins & Factor XA Inhibitors*)
- Platelet Aggregation Inhibitors

**Central Nervous System**

- Antihyperkinesia/CNS Stimulants (**Closed class**)
- Multiple Sclerosis Agents
- Non-Ergot Dopamine Receptor Agonists
- Neuropathic Pain
- Skeletal Muscle Relaxants
- Smoking Cessation Agents

**Contraceptives**

- Long-Acting Reversible Contraceptives (*includes IUDs & injectables*)

**Dermatologic Agents (Topical)**

- Acne Agents (*includes benzoyl peroxide, clindamycin, retinoids & combinations*)
- Antifungal Agents
- Antivirals
- Psoriasis Agents
- Rosacea Agents

**Endocrine and Metabolic Agents**

- Androgenic Agents
- Bone Resorption Suppression and Related Agents (*includes bisphosphonates, calcitonins and others*)
- Estrogens (*vaginal and oral*)
- Hypoglycemics: Alpha-Glucosidase Inhibitors
- Hypoglycemics: Incretin Mimetics/Enhancers (*includes DPP-IV Inhibitors, GLP-1 Agonists & comb*) (**Closed class**)
- Hypoglycemics: Insulins
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformins
- Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (**Closed class**)
- Hypoglycemics: Sulfonylureas
- Hypoglycemics: Thiazolidinediones
- Pancreatic Enzymes
- Progestational Agents

**Immunological Agents**

- Self-administered Cytokine & CAM Antagonists with Related Agents including Methotrexate (*all indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS)*) (**Closed class**)

**Confidential Meeting (Pricing Information Discussion)**

**P&T Committee Members & DMAS Staff**

**Criteria Discussion of Phase I New Drugs**

**P&T Committee Members**

**Criteria Discussion of Phase II Drugs**

**P&T Committee Members**

**Next Meeting – October 18, 2018 (tentative)**

**Chair**

**Oral Presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes in Phase II which are scheduled for review at the April meeting and new drugs in PDL Phase I listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase II Annual Review – April 2017 to present
- New Drugs in PDL Phase I Drug Classes and Potential New Classes in Phase II – April 2016 to present

**No anecdotal accounts are to be given.** Each speaker will be allocated no more than 2 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) and [dfmoody@magellanhealth.com](mailto:dfmoody@magellanhealth.com) by 5 p.m. EST on **Wednesday, March 21, 2018.**

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) by 5 p.m. EST **Wednesday, March 21, 2018.**